MX2021013010A - Composiciones y metodos para modular la actividad del complemento. - Google Patents
Composiciones y metodos para modular la actividad del complemento.Info
- Publication number
- MX2021013010A MX2021013010A MX2021013010A MX2021013010A MX2021013010A MX 2021013010 A MX2021013010 A MX 2021013010A MX 2021013010 A MX2021013010 A MX 2021013010A MX 2021013010 A MX2021013010 A MX 2021013010A MX 2021013010 A MX2021013010 A MX 2021013010A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- complement
- release formulations
- modulate
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dispersion Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962837978P | 2019-04-24 | 2019-04-24 | |
| US201962947183P | 2019-12-12 | 2019-12-12 | |
| US201962947188P | 2019-12-12 | 2019-12-12 | |
| PCT/US2020/029733 WO2020219822A1 (en) | 2019-04-24 | 2020-04-24 | Compositions and methods for modulating complement activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021013010A true MX2021013010A (es) | 2022-01-18 |
Family
ID=70977557
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021013010A MX2021013010A (es) | 2019-04-24 | 2020-04-24 | Composiciones y metodos para modular la actividad del complemento. |
Country Status (13)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR122021025449B1 (pt) | 2014-06-12 | 2024-02-15 | Ra Pharmaceuticals, Inc | Composto, polipeptídeo e composição compreendendo o mesmo |
| SMT202100688T1 (it) | 2015-01-28 | 2022-01-10 | Ra Pharmaceuticals Inc | Modulatori di attività del complemento |
| KR20260070290A (ko) | 2015-12-16 | 2026-05-18 | 유씨비 홀딩스 인코포레이티드 | 보체 활성의 조절인자 |
| JP7301741B2 (ja) | 2016-12-07 | 2023-07-03 | ラ ファーマシューティカルズ インコーポレイテッド | 補体活性のモジュレータ |
| SG11202103972SA (en) * | 2018-10-22 | 2021-05-28 | Ra Pharmaceuticals Inc | Neurological disease treatment with zilucoplan |
| ES2973767T3 (es) | 2019-06-04 | 2024-06-24 | Ra Pharmaceuticals Inc | Tratamiento de enfermedades inflamatorias con inhibidores del complemento |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1241139A (zh) * | 1996-12-20 | 2000-01-12 | 武田药品工业株式会社 | 生产缓释制剂的方法 |
| AU1705100A (en) | 1998-10-09 | 2000-05-01 | Musc Foundation For Research Development | Blocking factor b to treat complement-mediated immune disease |
| EP2266606B1 (en) | 2003-05-15 | 2014-09-10 | Genentech, Inc. | Methods and compositions for the prevention and treatment of sepsis |
| CN1289066C (zh) * | 2003-09-18 | 2006-12-13 | 中国人民解放军第二军医大学 | 胰高血糖素样肽-1缓释微球制剂及其用途 |
| US20060270590A1 (en) | 2005-03-29 | 2006-11-30 | Lockwood Samuel F | Reduction in complement activation and inflammation during tissue injury by carotenoids, carotenoid analogs, or derivatives thereof |
| CN103505728A (zh) | 2005-05-26 | 2014-01-15 | 科罗拉多大学评议会法人机构 | 用于治疗外伤性脑损伤、脊髓损伤及相关病症的补体旁路抑制 |
| CN101374554A (zh) | 2005-09-27 | 2009-02-25 | 埃弗拉特生物聚合物有限公司 | 胶凝疏水性可注射聚合物组合物 |
| DK2500030T4 (en) | 2005-11-04 | 2018-10-29 | Genentech Inc | Use of complement pathway inhibitors for the treatment of eye diseases |
| CN101341254A (zh) * | 2005-12-24 | 2009-01-07 | 蒂加斯克乳制品研究中心 | 反-10,顺-12十八碳二烯酸的生产方法 |
| US20090028832A1 (en) * | 2006-08-10 | 2009-01-29 | Chung Leland F | Compositions and methods for targeted tumor therapy |
| LT3028716T (lt) | 2006-10-10 | 2020-12-10 | Regenesance B.V. | Komplemento slopinimas nervų regeneracijos pagerinimui |
| US7736860B2 (en) | 2006-11-09 | 2010-06-15 | Univeristy Of Massachusetts | Methods of identifying compounds for the treatment of sterile inflammation |
| US20100015139A1 (en) | 2008-07-10 | 2010-01-21 | Rekha Bansal | METHOD OF INHIBITING COMPLEMENT ACTIVATION WITH FACTOR Ba SPECIFIC ANTIBODIES AND USE THEREOF |
| RU2009144142A (ru) | 2007-04-30 | 2011-06-10 | Алькон Рисерч, Лтд. (Us) | Лечение возрастной дегенерации желтого пятна с применением ингибиторов фактора d комплемента |
| AU2008262048B2 (en) | 2007-06-07 | 2013-09-26 | Genentech, Inc. | C3b antibodies and methods for the prevention and treatment of complement- associated disorders |
| WO2009014633A1 (en) | 2007-07-20 | 2009-01-29 | Trustees Of The University Of Pennsylvania | Method of treating acute respiratory distress syndrome |
| JP5473925B2 (ja) | 2007-10-27 | 2014-04-16 | コーデン ファーマ コロラド インコーポレイテッド | 固相および溶液相の組み合わせ技法を使用するインスリン分泌性ペプチドの合成 |
| US20110172126A1 (en) | 2008-09-03 | 2011-07-14 | Xenome Ltd | Libraries of peptide conjugates and methods for making them |
| US20100086596A1 (en) * | 2008-10-06 | 2010-04-08 | Oakwood Laboratories LLC | Microspheres for releasing an octreotide compound without an initial time lag |
| JP6223659B2 (ja) | 2008-11-10 | 2017-11-01 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | 補体関連障害を処置するための方法および組成物 |
| EP3150635A3 (en) | 2009-10-16 | 2017-06-21 | Omeros Corporation | Methods for treating disseminated intravascular coagulation by inhibiting masp-2 dependent complement activation |
| WO2011106635A1 (en) | 2010-02-25 | 2011-09-01 | The Trustees Of The University Of Pennsylvania | Treatment of sepsis using complement inhibitors |
| WO2011137363A1 (en) | 2010-04-30 | 2011-11-03 | Allergan, Inc. | Novel treatment for age related macular degeneration and ocular ischemic disease associated with complement activation by targeting 5-lipoxygenase |
| TW201241008A (en) * | 2010-10-01 | 2012-10-16 | Alexion Pharma Inc | Polypeptides that bind to human complement component C5 |
| DK2694108T3 (en) | 2011-04-08 | 2018-08-20 | Univ Leicester | METHODS OF TREATING DISEASES ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION |
| WO2012162215A1 (en) | 2011-05-20 | 2012-11-29 | The Trustees Of The University Of Pennsylvania | Promotion of fracture healing using complement inhibitors |
| WO2012174055A1 (en) | 2011-06-13 | 2012-12-20 | The Trustees Of The University Of Pennsylvania | Wound healing using complement inhibitors |
| US20130246083A1 (en) | 2012-03-16 | 2013-09-19 | Alexion Pharmaceuticals, Inc. | Methods of distributing complement-inhibiting drugs to patients receiving a complement inhibitor |
| US9579360B2 (en) | 2012-06-20 | 2017-02-28 | The Trustees Of The University Of Pennsylvania | Methods of treating or preventing periodontitis and diseases associated with periodontitis |
| WO2014004733A1 (en) | 2012-06-26 | 2014-01-03 | The Regents Of The University Of California | Composition for lupus nephritis and methods of making and using the same |
| WO2014078622A1 (en) | 2012-11-15 | 2014-05-22 | The Brigham And Women's Hospital, Inc. | Method and system for diagnosing and treating preeclampsia |
| US20140234275A1 (en) | 2013-02-15 | 2014-08-21 | Jason Williams | Method for treating als via the increased production of factor h |
| EP3089742A4 (en) * | 2013-12-31 | 2017-08-02 | Heron Therapeutics, Inc. | Polymer-based compositions for extended release of proteins |
| BR122021025449B1 (pt) | 2014-06-12 | 2024-02-15 | Ra Pharmaceuticals, Inc | Composto, polipeptídeo e composição compreendendo o mesmo |
| WO2016138520A1 (en) | 2015-02-27 | 2016-09-01 | The Johns Hopkins University | Assay to diagnose and treat disorders of the alternative pathway of complement activation |
| KR20260070290A (ko) * | 2015-12-16 | 2026-05-18 | 유씨비 홀딩스 인코포레이티드 | 보체 활성의 조절인자 |
| US20170333304A1 (en) * | 2016-05-20 | 2017-11-23 | Massachusetts Institute Of Technology | Hydrogel Particles, Compositions, and Methods |
| JP7301741B2 (ja) | 2016-12-07 | 2023-07-03 | ラ ファーマシューティカルズ インコーポレイテッド | 補体活性のモジュレータ |
| DK3411400T3 (da) * | 2017-04-03 | 2021-10-11 | Inflarx Gmbh | Behandling af inflammatoriske sygdomme med hæmmere af c5a-aktivitet |
-
2020
- 2020-04-24 CN CN202080030772.3A patent/CN113710230A/zh active Pending
- 2020-04-24 SG SG11202109837S patent/SG11202109837SA/en unknown
- 2020-04-24 EP EP20730497.3A patent/EP3958842B1/en active Active
- 2020-04-24 US US17/605,495 patent/US20220211799A1/en active Pending
- 2020-04-24 BR BR112021017820A patent/BR112021017820A2/pt not_active Application Discontinuation
- 2020-04-24 AU AU2020261059A patent/AU2020261059A1/en not_active Abandoned
- 2020-04-24 WO PCT/US2020/029733 patent/WO2020219822A1/en not_active Ceased
- 2020-04-24 CA CA3137895A patent/CA3137895A1/en active Pending
- 2020-04-24 KR KR1020217034548A patent/KR20220004039A/ko not_active Withdrawn
- 2020-04-24 JP JP2021562971A patent/JP7726791B2/ja active Active
- 2020-04-24 TW TW109113822A patent/TW202106290A/zh unknown
- 2020-04-24 MX MX2021013010A patent/MX2021013010A/es unknown
-
2021
- 2021-10-07 IL IL287079A patent/IL287079A/en unknown
-
2025
- 2025-04-02 JP JP2025060888A patent/JP2025118607A/ja active Pending
- 2025-10-22 US US19/366,293 patent/US20260216276A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025118607A (ja) | 2025-08-13 |
| CA3137895A1 (en) | 2020-10-29 |
| US20220211799A1 (en) | 2022-07-07 |
| SG11202109837SA (en) | 2021-10-28 |
| CN113710230A (zh) | 2021-11-26 |
| WO2020219822A1 (en) | 2020-10-29 |
| EP3958842B1 (en) | 2026-07-29 |
| EP3958842A1 (en) | 2022-03-02 |
| BR112021017820A2 (pt) | 2022-02-08 |
| TW202106290A (zh) | 2021-02-16 |
| JP7726791B2 (ja) | 2025-08-20 |
| KR20220004039A (ko) | 2022-01-11 |
| AU2020261059A1 (en) | 2021-10-14 |
| JP2022530042A (ja) | 2022-06-27 |
| IL287079A (en) | 2021-12-01 |
| US20260216276A1 (en) | 2026-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP22052564A (es) | Tetrahidrofuranos sustituidos como moduladores de canales de sodio | |
| CO2022002781A2 (es) | Receptores agonistas no peptídicos de somatostatina tipo 5 y usos de los mismos | |
| ECSP19070369A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| CL2021000741A1 (es) | Composiciones plaguicidas sinérgicas y métodos para distribución de ingredientes activos insecticidas | |
| CL2019002671A1 (es) | Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1. | |
| CL2020001990A1 (es) | Moduladores del receptor nmda espiro-lactama y usos de los mismos. (hna. 1991-20) | |
| ECSP19083621A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| ECSP22076856A (es) | Inhibidores de rip1k | |
| ECSP19070413A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| CL2022000998A1 (es) | Inhibidores de las cinasas raf | |
| BR112022010754A2 (pt) | Análogos de rapamicina e usos dos mesmos | |
| ECSP19083640A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| UY40873A (es) | Compuestos cíclicos puenteados y composiciones farmacéuticas y usos de los mismos para modular la respuesta integrada al estrés y para tratar enfermedades relacionadas | |
| CL2020001991A1 (es) | Moduladores del receptor nmda espiro-lactama y usos de los mismos. (hna. 1990-20) | |
| ECSP18073293A (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue | |
| BR112021017820A2 (pt) | Composições e métodos para modulação da atividade de complemento | |
| BR112019001768A2 (pt) | moduladores do receptor de spiro-lactamas nmda e usos dos mesmos | |
| ECSP19084085A (es) | Inhibidores pirazólicos de magl | |
| ECSP18073366A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| MX394098B (es) | Compuestos inhibidores de ask1 y usos de los mismos | |
| BR112018073663A2 (pt) | moduladores de receptores nmda spiro-lactâmicos e seus usos | |
| MX2020011405A (es) | Derivados de bencimidazol como moduladores del receptor gamma huerfano (rory) relacionado con retinoide y usos farmaceuticos de los mismos. | |
| MX2022000646A (es) | Derivados de n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-4 ,5,6,7- tetrahidrobenzofuran-2-sulfonamida y compuestos relacionados como moduladores de nlpr3 para el tratamiento de esclerosis múltiple (ms). | |
| BR112019001923A2 (pt) | moduladores de nmda de espiro-lactama e métodos de sua utilização | |
| CL2012000013A1 (es) | Compuestos derivados de 4-{3-[3-(4-trifluorometil-fenil)ureido]-5-fluoro-bencilamino}-1h-pirazol-3-carboxamida; procedimiento de preparacion; composicion farmaceutica que los comprende; compuestos intermediarios; y su uso como moduladores de la actividad de las proteinas quinasa para el tratamiento del cancer. |